Nanobiotix aims to expand life - using nanophysics to overcome major diseases with disruptive solutions developed and executed by people who want to change the world.

The company is primarily focused on development of its lead product candidate: NBTXR3. NBTXR3 is a first-in-class radioenhancer composed of functionalized hafnium oxide nanoparticles. The product is administered via one-time intra-tumoral injection and activated by radiation therapy. When activated, the physical and universal mode of action of NBTXR3 is designed to trigger cellular destruction along with adaptive immune response.